MarketCap
Cellectar Biosciences CLRB
$ 1.24
-3.88%
Facebook
X
Telegram
Cellectar Biosciences ROCE Ratio | CLRB
Annual ROCE Ratio Cellectar Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -259.76 | -352.13 | 265.67 | -330.96 | -82.56 | -27.75 | -149.55 | -86.77 | -126.44 | -69.02 | -451.81 | -86.06 | -468.7 | -81.86 | -73.96 | -107.6 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 265.67 | -468.7 | -155.58 |
Quarterly ROCE Ratio Cellectar Biosciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -240.21 | -264.57 | -335.31 | -290.28 | -312.63 | -339.87 | -352.99 | -374.9 | -202.66 | -82.97 | 129.37 | 106.68 | -40.18 | -115.72 | -243.85 | -125.16 | -145.43 | -99.13 | -71.47 | -61.61 | -48.41 | -39.96 | -33.49 | -20.79 | -62.6 | -89.28 | -121.02 | -113.85 | -136.83 | -116.65 | -108.61 | -70.32 | -102.71 | -109.63 | -114.14 | -88.43 | -106.46 | -91.11 | -75.82 | -49.68 | -160.2 | -263.18 | -382.8 | -368.19 | -399.82 | -324.72 | -242.94 | -106.28 | -233.22 | -320.34 | -403.21 | -363.98 | -383.1 | -276.74 | -179.64 | -61.34 | -80.34 | -83.64 | -71.54 | -49.89 | -19.0 | -22.41 | -8.49 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 129.37 | -403.21 | -158.22 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-57.94 | $ 4.13 | -2.5 % | $ 506 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-13.71 | $ 29.38 | -2.91 % | $ 4.46 B | USA |
 |
Larimar Therapeutics
LRMR
|
-220.91 | $ 2.68 | 5.93 % | $ 223 M | USA |
 |
Biofrontera AG
BFRA
|
-15.82 | - | -8.24 % | $ 105 M |  Germany |
 |
Pliant Therapeutics
PLRX
|
-86.3 | $ 0.78 | -2.19 % | $ 47.9 M | USA |
 |
Pharming Group N.V.
PHAR
|
23.99 | $ 13.02 | -1.06 % | $ 8.97 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-91.16 | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
-33.78 | $ 8.91 | -9.54 % | $ 414 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
9.54 | $ 29.06 | -1.09 % | $ 1.36 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
9.21 | - | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
-62.98 | $ 3.52 | -0.56 % | $ 376 M | USA |
 |
Jaguar Health
JAGX
|
245.65 | $ 0.44 | -0.21 % | $ 1.03 M | USA |
 |
Arvinas
ARVN
|
-20.59 | $ 6.9 | 2.07 % | $ 489 M | USA |
 |
Cerus Corporation
CERS
|
-7.22 | $ 1.95 | -6.04 % | $ 372 M | USA |
 |
Beam Therapeutics
BEAM
|
-27.72 | $ 25.16 | -6.88 % | $ 2.49 B | USA |
 |
Pulmatrix
PULM
|
-35.98 | $ 1.39 | 2.58 % | $ 5.08 B | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 1.9 | -4.52 % | $ 53 M | USA |
 |
Inhibrx
INBX
|
-503.92 | $ 90.63 | -1.21 % | $ 4.27 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-83.6 | $ 3.24 | -0.31 % | $ 150 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
-47.3 | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-12.44 | $ 20.25 | -16.63 % | $ 7.46 B | USA |
 |
CytomX Therapeutics
CTMX
|
-21.31 | $ 2.0 | 0.76 % | $ 276 M | USA |
 |
Krystal Biotech
KRYS
|
13.1 | $ 306.47 | 1.13 % | $ 8.87 B | USA |
 |
Kura Oncology
KURA
|
-48.86 | $ 7.56 | -0.13 % | $ 663 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-30.06 | $ 1.58 | -6.25 % | $ 155 M | USA |
 |
Heron Therapeutics
HRTX
|
-1.59 | $ 0.38 | 1.38 % | $ 63.3 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-283.35 | $ 1.47 | -2.98 % | $ 68.9 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-69.6 | $ 11.36 | 0.09 % | $ 897 M | USA |
 |
Aytu BioScience
AYTU
|
-16.52 | $ 1.83 | 2.23 % | $ 22.5 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
-20.73 | - | -5.76 % | $ 99.8 M | USA |
 |
Innoviva
INVA
|
13.96 | $ 19.08 | 0.39 % | $ 1.29 B | USA |
 |
BioCardia
BCDA
|
-924.92 | $ 0.95 | 2.66 % | $ 6.33 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-17.68 | - | 0.11 % | $ 419 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 2.3 | -5.35 % | $ 14.7 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-8.2 | - | -3.90 % | $ 97.2 M | China |
 |
Millendo Therapeutics, Inc.
MLND
|
-101.55 | - | -5.36 % | $ 20.2 M | USA |
 |
Certara
CERT
|
1.5 | $ 12.21 | -0.08 % | $ 1.96 B | USA |
 |
Dyadic International
DYAI
|
-583.64 | $ 0.39 | 1.16 % | $ 14.1 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-88.86 | - | -12.45 % | $ 17.7 M | Israel |
 |
Anika Therapeutics
ANIK
|
-7.7 | $ 13.42 | -7.89 % | $ 192 M | USA |
 |
Aprea Therapeutics
APRE
|
-106.37 | $ 0.45 | -9.44 % | $ 2.94 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 3.4 | -1.73 % | $ 217 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
6.68 | $ 73.22 | -2.41 % | $ 7.6 B | USA |
 |
Progenity, Inc.
PROG
|
-238.7 | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
-194.87 | $ 2.1 | 1.94 % | $ 1.96 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
-43.18 | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-207.17 | $ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
-108.46 | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.99 | $ 57.1 | -0.14 % | $ 11 B | USA |